American hematologist-oncologist and health researcher
Moderna’s mFlusiva has secured an advisory committee vote in favor of approval for adults 50 and older. The decision follows earlier FDA scrutiny and a high-profile dispute over study design, with the committee citing robust efficacy and a solid safety profile.
Moderna has won FDA approval for its mRNA flu vaccine mFlusiva for adults 50–64 and accelerated approval for those 65 and older. The decision follows a contentious review earlier this year, a unanimous advisory panel recommendation in June and political disputes inside US health agencies over mRNA vaccines. Retail availability is expected in coming weeks.